Literature DB >> 24163989

Comparative study: single-incision laparoscopic cholecystectomy and conventional three-ports laparoscopic cholecystectomy.

Chinda Akethong1, Thiti Sawaengtham.   

Abstract

BACKGROUND: Laparoscopic cholecystectomy is now standard treatment of gallstone disease and has traditionally been performed using multiple small sites. Single-incision laparoscopic surgery has emerged as an alternative technique to improve cosmesis and minimize complications associated with multiple incisions pain and longer hospital stay. MATERIAL AND
METHOD: Between January 2010 and December 2012, 40 patients were assigned to one of the two groups, SILS-C or conventional LC. Surgical indication, operative time, length of stay, and surgical complications were compared between the two groups.
RESULTS: Twenty patients underwent SILS-C and 20 patients underwent conventional three ports LC. The average length of stay was 2.60 +/- 0.88 days after SILS-C compared with 2.65 +/- 0.87 days after CLC (p = 0.871). Operative time was significantly longer in the SILS-C group. An average of 65 minutes was needed to complete a SILS-C (range 35-141) versus 51 minutes (range 24-109) for a CLC (p < 0.001). There was no difference in pain score and complications between both groups but SILS-C group use less analgesic (81.00 +/- 36.55 mg in SILS-C vs. 123.00 +/- 42.31 mg in the conventional group).
CONCLUSION: The Single Incision Laparoscopic Cholecystectomy (SILS-C) is feasible and safe. The results of SILS-C were comparable with the standard conventional LC.

Entities:  

Mesh:

Year:  2013        PMID: 24163989

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Single-incision laparoscopic cholecystectomy with curved versus linear instruments assessed by systematic review and network meta-analysis of randomized trials.

Authors:  Stavros A Antoniou; Salvador Morales-Conde; George A Antoniou; Rudolph Pointner; Frank-Alexander Granderath
Journal:  Surg Endosc       Date:  2015-06-23       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.